Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser

NCT01441895 | Unknown

• 1 other identifier: AGN02-FEMTO
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The study objective is to assess changes in corneal sensation and dry eye signs and symptoms following cataract extraction/femtosecond arcuate relaxing incisions. Our clinical hypothesis is to determine if a combination of cataract surgery and femtosecond arcuate relaxing incisions lead to a reduction in corneal sensation and the onset or worsening of dry eye signs and symptoms.

Conditions

Cataract; Dry Eye

Keywords

Refractive Cataract Extraction; Femtosecond laser; arcuate relaxing incisions; Dry Eye post cataract refraction

Outcome Measures

Primary Outcomes (1)

• Change in Corneal Sensitivity Testing

  Subject lies supine with the test line of the Cochet-Bonnet Aesthesiometer suspended over the cornea to measure the sensation of touch on the eye. Testing is done in a standard manner by an experienced operator.

  Change from Screening to Month 3

Secondary Outcomes (7)

• Ocular Surface Disease Index (OSDI)

  Change from Screening to Month 3

• Subject Dry Eye Questionnaire

  Change from Screening to Month 3

• Artificial Tear Use

  Change from Screening to Month 3

• Corneal and Conjunctival Staining

  Change from Screening to Month 3

• Tear Break Up Time (TBUT) with Biomicroscopy

  Change from Screening to Month 3

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Private Practice

You may qualify if:

• Male or female subjects 18 years or older, in good general health
• Prior to signing the Institutional Review Board approved Informed Consent Form / Health Insurance Portability and Accountability Act subject read and gained an understanding of the contents
• Subject scheduled for cataract extraction with intraocular lens and requiring two (2) femtosecond arcuate relaxing incisions for correction of corneal astigmatism
• Subject has greater than or equal to 1.0 D and less than or equal to 2.5 Diopters of corneal astigmatism as measured by keratometry or corneal topography
• Two (2) arcuate incisions should be 45° in length and 180° apart.
• All arcuate relaxing incisions will be placed exactly 4.5 mm from the visual axis for a 9 mm optical zone.
• Corneal sensation at Screening by Cochet-Bonnet Aesthesiometry with floor stand \>50 mm in all five regions
• Be willing / able to return for all required study visits and comply with instructions given by study staff
• Potential for best corrected visual acuity post cataract surgery of 20/20

You may not qualify if:

• Uncontrolled inflammation not related to dry eye
• Corneal abnormality that can affect corneal sensation or tear film stability (except superficial punctate keratitis (SPK)).
• History of ophthalmic herpes simplex or zoster keratitis
• OSDI score \> 32
• Active ocular allergy
• History of refractive surgery or any surgery involving conjunctival, arcuate or corneal incision
• Contact lens wear during the study. Soft contact lens wearers should discontinue use at least two weeks prior to Screening visit. Rigid gas permeable (RGP) or hard contact lens wearers should discontinue use at least one month prior to Screening visit.
• Dry eye secondary to Vitamin A deficiency, scarring, pemphigoid, alkali burns, Stevens-Johnson syndrome, trachoma, or irradiation.
• Currently using, or have used within 14 days of study enrollment, any ocular medications other than artificial tears
• Use of topical cyclosporine (Restasis) within three months of Screening visit.
• Have an uncontrolled systemic disease (e.g., hypertension, diabetes) or the presence of any significant illness (e.g., serious gastrointestinal, renal, hepatic, endocrine, pulmonary, cardiac, neurological disease, cancer, AIDS, or cerebral dysfunction) that could, in the judgment of the investigator, jeopardize subject safety or interfere with the interpretation of the results of the study
• Temporary or permanent occlusion of the lacrimal puncta
• Require chronic use of systemic medications which may induce or affect a dry eye condition (e.g., anticholinergics, cyclosporine, antihistamines, antimuscarinics, beta-blocking agents, tricyclic antidepressants, phenothiazines, estrogen-progesterone, and other estrogen derivatives), unless that medication has been used in the same dose for at least 3 months and is expected to remain constant for the course of the study
• Current or anticipated use of nutritional supplements (e.g. flax seed oil, fish oil, omega-3 supplements) which may affect a dry eye condition.
• Are currently enrolled in any other clinical study or have participated in such a study within 30 days of entry into this study

Sponsors & Collaborators

• Ophthalmic Consultants of Long Island: lead
• Allergan: collaborator

Study Sites (1)

Ophthlamic Consultants of Long Island - Rockville Centre

Rockville Centre, New York, 11570, United States

RECRUITING

MeSH Terms

Conditions

Cataract; Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lens Diseases; Eye Diseases; Lacrimal Apparatus Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2011
• First Posted: September 28, 2011
• Study Start: September 1, 2011
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: April 25, 2016

Record last verified: 2016-04

Locations

US (1)